Allogene Therapeutics Uses Standard FC Regimen in ALPHA3 Trial for Cema-Cel
Allogene Therapeutics has discontinued the fludarabine, cyclophosphamide, and ALLO-647 (FCA) arm of its pivotal ALPHA3 study in first-line large...
Jon Napitupulu
Artelo Gets UK Approval for Phase 1 Trial of CBD:TMP Cocrystal
Artelo Biosciences has received positive scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its...
BioXcel Concludes In-Home Agitation Trial for Bipolar and Schizophrenia
BioXcel Therapeutics has completed the last patient visit in its pivotal Phase 3 SERENITY At-Home trial of BXCL501 (dexmedetomidine)...
Orchestra Biomed Secures $70M Strategic Investment
Orchestra BioMed (OBIO) has secured $70 million in new funding from Ligand Pharmaceuticals and existing partner Medtronic, bolstering its...
Supernus Pharma Completes Sage Therapeutics Acquisition
Supernus Pharmaceuticals has completed its acquisition of Sage Therapeutics. The deal brings Sage’s recently approved postpartum depression (PPD) drug,...
Myriad Genetics Secures $200M Credit Facility
Myriad Genetics secured a five-year, $200 million senior secured term loan from OrbiMed, replacing its previous asset-based lending (ABL)...
Immuthera and Poltreg Secure FDA Nod for T1D Trial
The FDA has signaled its acceptance of PolTREG’s existing clinical data in Stage 3 Type 1 diabetes (T1D) as...
UCLA Health Joins Briacell’s Pivotal Breast Cancer Study
BriaCell Therapeutics has added UCLA Health Jonsson Comprehensive Cancer Center as a clinical site for its ongoing Phase 3...
Real-world Leqembi® Study Data at AAIC 2025
Real-world data from 178 early Alzheimer’s disease (AD) patients treated with lecanemab show an 87.4% treatment continuation rate at...
Trethera Gets FDA Clearance for TRE-515 Clinical Trial
The FDA has cleared Trethera Corporation to initiate a clinical trial evaluating TRE-515 in healthy volunteers. This trial will...